The three reports [18], [20], [21] about the impact of IL28B on the treatment outcomes of chronic hepatitis C GT2 or GT3 patients showed IL28B polymorphism was associated with SVR in the 24-week treatment and the effect was only observed in the non-RVR patients. Here, IFNL3 is linked to chronic hepatitis C virus infection.